(T24). Moreover, these two groups were further stratified into subgroups based on whether or not subjects had meniscal extrusion at baseline and further on whether or not they received a combination of Glu and CS. The main outcomes were knee structural changes including the loss of joint space width (JSW) and cartilage volume loss measured by quantitative MRI (qMRI). Results: Participants reported taking (þ) (n¼300) or not taking (-) (n¼300) OA treatment (analgesics/NSAIDs) over 24 months, with or without Glu/CS. The participants with meniscal extrusion had more knee OA structural damage at baseline and more knee OA progression as assessed by both X-rays and qMRI. Patients in both -and þanalgesics/ NSAIDs groups with meniscal extrusion had significantly greater cartilage volume loss in the medial compartment compared to those without meniscal extrusion. No significant effect on JSW loss was found at T24 between -and þanalgesics/NSAIDs groups, regardless of the presence or absence of meniscal extrusion and of the consumption or not of Glu/CS, whereas significant differences emerged for cartilage volume loss when examined by qMRI. In the -analgesics/NSAIDs group (mild disease) with meniscal extrusion (more progressive disease) participants taking Glu/CS had less cartilage volume loss in the plateau (p¼0.01). Multivariate analyses further confirmed in the -analgesics/NSAIDs group, that those with meniscal extrusion who took Glu/CS had significantly less cartilage volume loss in the medial plateau (p¼0.009). In the þanalgesics/NSAIDs group, at T24, participants without meniscal extrusion (moderate disease) taking Glu/CS had less cartilage volume loss in the global (p0.002, univariate and multivariate analyses) and medial and lateral plateaus (p¼0.034, p¼0.013, respectively, multivariate analysis). However, in participants with meniscal extrusion (severe disease), although those taking Glu/CS had significantly less cartilage volume loss in the medial condyle at T24 in univariate analysis, this finding was not confirmed in multivariate analysis. Conclusions: The presence of meniscal extrusion is an important factor that can influence the drug effect on cartilage volume. X-rays were found to be much less sensitive than MRI at documenting the protective effect of treatment on structural changes. Indeed, with qMRI, the -analgesics/NSAIDs group subjects with meniscal extrusion (mild but progressive disease) demonstrated that Glu/CS prevented cartilage volume loss in the medial plateau with a trend in the medial tibiofemoral compartment (Figure 1 ). In the þanalgesics/NSAIDs group, the Glu/CS prevented cartilage volume loss in the global plateau in the subjects without meniscal extrusion (moderate disease) (Figure 2) . The non-effect of Glu/CS on patients without meniscal extrusion not taking analgesics/NSAIDs, representing very mild disease, probably reflects that the cartilage volume loss was small and unlikely to provide an accurate estimate. Moreover, in subjects with meniscal extrusion who took analgesics/NSAIDs (severe disease), the non-effect observed likely reflects irreversible cartilage damage. This study confirms that combined administration of Glu/CS has a significant beneficial effect at delaying knee OA cartilage volume loss in subjects with mild to moderate disease severity.
CARNOSIC ACID INDUCES HEME OXYGENASE-1 AND SUPPRESSES PROTEOGLYCAN RELEASE
H. Ishitobi, C. Shibata, S. Yamasaki, S. Miyaki, K. Matsubara. Hiroshima Univ., Hiroshima, Japan Purpose: Osteoarthritis (OA) is associated with age-related loss of cartilage homeostatic balance. Antioxidant and autophagy are an important mechanism to maintain cellular homeostasis under various stresses and its activity decreases with aging and OA development. Recently, we reported that the deficiency of Bach1, transcriptional repressor, reduces the severity of OA-like changes through upregulated heme oxygenase-1 (HO-1), which is cytoprotective through its antioxidant effects. Thus, enhancement of HO-1 may prevent age-related diseases such as OA. Several foods are also effective as prevention of oxidant stress. Epidemiology data suggest that high intake of fruit and vegetables protect against the onset and/or progression of OA. Carnosic acid (CA) is a natural compound in rosemary and common sage, and it has the cytoprotective effects via the potential of antioxidant and antiinflammation. The object of this study was to examine whether CA would be effective for OA prevention. Methods: Human synovial fibroblasts and chondrocytes were obtained from Dr. Martin K Lotz (The Scripps Research Institute, USA). Normal human knee synovial fibroblasts and chondrocytes were isolated from autopsy donors as leftover de-identified material and with no interactions with subjects, and therefore with no informed consent required. The human chondrocyte and synovial fibroblast was plated at 5 x 104 per well into 24 well plates. These cells were treated with 1, 5, 10, 25, 50 mM CA for 24 h. The expression of HO-1 and autophagy marker LC3 was analysed using immunoblotting. We examined whether the expression of OA-related genes COL2a1, AGGRECAN, IL-1b, IL-6, MMP-3, -13 and ADAMTS-5 can be regulated by CA, when synovial fibroblasts and chondrocytes were stimulated with IL-1b (1 ng/ml) for 24 h. To examine whether CA effects on prevention of cartilage degradation, we performed Glycosaminoglycan (GAG) release assay using mouse cartilage explants. Femoral heads were harvested from 4-week-old C57BL/6 mice and incubated at 37 C for 72 h in 48-well plates. The cartilage samples were cultured for 72h in 500 ml of serum-free DMEM containing CA 10 or 50 mM with or without IL-1b.
For studies on CA drinking, we evaluated the levels of HO-1 in response to CA drinking in the knee joints by immunohistochemistry. Furthermore, the senescence-accelerated mouse (SAMP8) was used as a primary OA, and 3-months old male SAMP8 mice were bred with free access to drinking water including CA (50 mM) for 10-months. The knee joints were stained with Safranin O and grade by the OA scoring systems. Results: The expression of HO-1 was upregulated in human synovial fibroblasts and chondrocytes treated with CA in a dose-dependent manner. LC3 was not induced by CA. CA had no effect on the expression of Col2a1 and AGGRECAN in chondrocytes. Although the expression of IL-1b, IL-6, MMP-3, -13 and ADAMTS-5 was upregulated by IL-1b in the human synovial fibroblasts and chondrocytes, the expression of IL-1b, MMP-13 was significantly downregulated by CA. In GAG release assay using cartilage explants, CA decreased proteoglycan release. Finally, to determine whether CA would be effective in OA model mice as a supplement, we performed the histologic evaluation of knee joints in SAMP8. Although the severity of cartilage destruction was trend towards differences in the CA drinking group compared with control group, none of the differences were statistically significant. HO-1 was not markedly induced by orally administered CA in joint tissues including cartilage, however, it suppressed age-related hepatic steatosis. Conclusions: This study showed that CA induced HO-1 in synovial fibroblasts and chondrocyte and suppressed proteoglycan release from cartilage via downregulation of IL-1b, MMP-13. However, orally administered CA could not prevent spontaneous age-related OA. These findings suggest that CA is an effective HO-1 inducer and have a potential to be supplement for OA prevention.
Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A338
